These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3754062)

  • 1. Heparin cofactor II activity in plasma: application of an automated assay method to the study of a normal adult population.
    Andersson TR; Larsen ML; Handeland GF; Abildgaard U
    Scand J Haematol; 1986 Jan; 36(1):96-102. PubMed ID: 3754062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma.
    Abildgaard U; Larsen ML
    Thromb Res; 1984 Aug; 35(3):257-66. PubMed ID: 6547786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Constitutional dysfunction of heparin cofactor II with a tendency for venous thrombosis].
    Marbet GA; Zbinden B; Duckert F
    Schweiz Med Wochenschr; 1988 Oct; 118(43):1586-8. PubMed ID: 3238395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consumption of heparin cofactor II (dermatan sulfate cofactor) and antithrombin during coagulation.
    Andersson TR
    Thromb Res; 1987 Apr; 46(2):355-62. PubMed ID: 3603428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin cofactor II: experimental approach to a new assay and clinical results.
    Vinazzer H; Stocker K
    Thromb Res; 1991 Feb; 61(3):235-41. PubMed ID: 2028443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma heparin cofactor II in alcoholic liver disease.
    Andersson TR; Bell H
    J Hepatol; 1988 Aug; 7(1):79-84. PubMed ID: 3183355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of interference by heparin cofactor II in the DuPont aca antithrombin-III assay.
    Hortin GL; Tollefsen DM; Santoro SA
    Am J Clin Pathol; 1988 Apr; 89(4):515-7. PubMed ID: 3354504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin cofactor II: a simple assay method and results of its clinical application.
    Vinazzer H; Pangraz U
    Thromb Res; 1987 Oct; 48(2):153-60. PubMed ID: 3424287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of heparin or dermatan sulfate to thrombin is essential for the sulfated polysaccharide-accelerated inhibition of thrombin by heparin cofactor II.
    Yamagishi R; Koide T; Sakuragawa N
    FEBS Lett; 1987 Dec; 225(1-2):109-12. PubMed ID: 3691797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Turnover study of heparin cofactor II in healthy man.
    Sié P; Dupouy D; Pichon J; Boneu B
    Thromb Haemost; 1985 Oct; 54(3):635-8. PubMed ID: 3841420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin cofactor II, antithrombin and protein C in plasma from term and preterm infants.
    Andersson TR; Bangstad H; Larsen ML
    Acta Paediatr Scand; 1988 Jul; 77(4):485-8. PubMed ID: 3394503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
    Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The second cofactor of heparin].
    Sie P
    Ann Biol Clin (Paris); 1987; 45(2):181-3. PubMed ID: 3619144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification and biological property of heparin cofactor II: activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans.
    Yamagishi R; Niwa M; Kondo S; Sakuragawa N; Koide T
    Thromb Res; 1984 Dec; 36(6):633-42. PubMed ID: 6084876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of an automated assay of effective heparin activity in plasma.
    Pierson-Perry JF; Obzansky DM; Mizzer JP
    Clin Chem; 1987 Sep; 33(9):1630-4. PubMed ID: 3621562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis.
    Toulon P; Jacquot C; Capron L; Frydman MO; Vignon D; Aiach M
    Thromb Haemost; 1987 Jun; 57(3):263-8. PubMed ID: 3660328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin cofactor II assay. Elimination of heparin and antithrombin-III effects.
    Nakhleh R; Vogt JM; Edson JR
    Am J Clin Pathol; 1988 Mar; 89(3):353-8. PubMed ID: 3348170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin cofactor II deficiency in the elderly: comparison with antithrombin III.
    Kario K; Matsuo T; Kobayashi H
    Thromb Res; 1992 Jun; 66(5):489-98. PubMed ID: 1381849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of purified dermatan sulfate for heparin cofactor II (HC II) assay.
    Ruzzenente O; Ghidini R; Poli G; Schiavon R; Guidi GC
    Thromb Res; 1992 Jan; 65(2):281-7. PubMed ID: 1579900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on the determination of heparin cofactor II (HC II) activity using a synthetic chromogenic substrate].
    Ohtsubo M; Asai M; Asai K; Takagi A
    Rinsho Byori; 1987 May; 35(5):565-70. PubMed ID: 3613167
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.